Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: An open-label pilot study

James Taylor Hays, Ivana T Croghan, Darrell R. Schroeder, Jon Owen Ebbert, Richard D. Hurt

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The purpose of this study was to obtain preliminary evidence of the efficacy of a 12-week course of varenicline for 7-day point prevalence smoking abstinence among recovering alcohol-dependent smokers. We enrolled 32 smokers with 6 months or more of recovery from alcohol dependence in an open-label clinical trial. Participants received varenicline 1 mg twice daily and 12 weeks of behavioral counseling. Participants were 69% men, 94% Caucasian, and smoking an average of 20.3 ± 5.0 cigarettes per day. After 12 weeks of treatment, 31% were biochemically confirmed 7-day point prevalence abstinent from smoking and 28% had prolonged smoking abstinence (2 weeks after target quit date onward). The most common adverse effects were mild to moderate nausea (28%) and sleep disturbance (19%). No serious adverse events were reported. Varenicline may be a useful aid for treating tobacco dependence among smokers who are in stable recovery from alcohol dependence. Further study of this treatment is warranted.

Original languageEnglish (US)
Pages (from-to)102-107
Number of pages6
JournalJournal of Substance Abuse Treatment
Volume40
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Tobacco Use Disorder
Smoking
Alcohols
Alcoholism
Therapeutics
Tobacco Products
Nausea
Counseling
Sleep
Clinical Trials
Varenicline

Keywords

  • Abstinence
  • Alcohol dependence
  • Smoking cessation
  • Tobacco use disorder
  • Varenicline

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology
  • Phychiatric Mental Health
  • Medicine (miscellaneous)

Cite this

Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers : An open-label pilot study. / Hays, James Taylor; Croghan, Ivana T; Schroeder, Darrell R.; Ebbert, Jon Owen; Hurt, Richard D.

In: Journal of Substance Abuse Treatment, Vol. 40, No. 1, 01.2011, p. 102-107.

Research output: Contribution to journalArticle

@article{dc34b0a18db74efe8606be466772feef,
title = "Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: An open-label pilot study",
abstract = "The purpose of this study was to obtain preliminary evidence of the efficacy of a 12-week course of varenicline for 7-day point prevalence smoking abstinence among recovering alcohol-dependent smokers. We enrolled 32 smokers with 6 months or more of recovery from alcohol dependence in an open-label clinical trial. Participants received varenicline 1 mg twice daily and 12 weeks of behavioral counseling. Participants were 69{\%} men, 94{\%} Caucasian, and smoking an average of 20.3 ± 5.0 cigarettes per day. After 12 weeks of treatment, 31{\%} were biochemically confirmed 7-day point prevalence abstinent from smoking and 28{\%} had prolonged smoking abstinence (2 weeks after target quit date onward). The most common adverse effects were mild to moderate nausea (28{\%}) and sleep disturbance (19{\%}). No serious adverse events were reported. Varenicline may be a useful aid for treating tobacco dependence among smokers who are in stable recovery from alcohol dependence. Further study of this treatment is warranted.",
keywords = "Abstinence, Alcohol dependence, Smoking cessation, Tobacco use disorder, Varenicline",
author = "Hays, {James Taylor} and Croghan, {Ivana T} and Schroeder, {Darrell R.} and Ebbert, {Jon Owen} and Hurt, {Richard D.}",
year = "2011",
month = "1",
doi = "10.1016/j.jsat.2010.08.009",
language = "English (US)",
volume = "40",
pages = "102--107",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers

T2 - An open-label pilot study

AU - Hays, James Taylor

AU - Croghan, Ivana T

AU - Schroeder, Darrell R.

AU - Ebbert, Jon Owen

AU - Hurt, Richard D.

PY - 2011/1

Y1 - 2011/1

N2 - The purpose of this study was to obtain preliminary evidence of the efficacy of a 12-week course of varenicline for 7-day point prevalence smoking abstinence among recovering alcohol-dependent smokers. We enrolled 32 smokers with 6 months or more of recovery from alcohol dependence in an open-label clinical trial. Participants received varenicline 1 mg twice daily and 12 weeks of behavioral counseling. Participants were 69% men, 94% Caucasian, and smoking an average of 20.3 ± 5.0 cigarettes per day. After 12 weeks of treatment, 31% were biochemically confirmed 7-day point prevalence abstinent from smoking and 28% had prolonged smoking abstinence (2 weeks after target quit date onward). The most common adverse effects were mild to moderate nausea (28%) and sleep disturbance (19%). No serious adverse events were reported. Varenicline may be a useful aid for treating tobacco dependence among smokers who are in stable recovery from alcohol dependence. Further study of this treatment is warranted.

AB - The purpose of this study was to obtain preliminary evidence of the efficacy of a 12-week course of varenicline for 7-day point prevalence smoking abstinence among recovering alcohol-dependent smokers. We enrolled 32 smokers with 6 months or more of recovery from alcohol dependence in an open-label clinical trial. Participants received varenicline 1 mg twice daily and 12 weeks of behavioral counseling. Participants were 69% men, 94% Caucasian, and smoking an average of 20.3 ± 5.0 cigarettes per day. After 12 weeks of treatment, 31% were biochemically confirmed 7-day point prevalence abstinent from smoking and 28% had prolonged smoking abstinence (2 weeks after target quit date onward). The most common adverse effects were mild to moderate nausea (28%) and sleep disturbance (19%). No serious adverse events were reported. Varenicline may be a useful aid for treating tobacco dependence among smokers who are in stable recovery from alcohol dependence. Further study of this treatment is warranted.

KW - Abstinence

KW - Alcohol dependence

KW - Smoking cessation

KW - Tobacco use disorder

KW - Varenicline

UR - http://www.scopus.com/inward/record.url?scp=78649801132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649801132&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2010.08.009

DO - 10.1016/j.jsat.2010.08.009

M3 - Article

C2 - 20947286

AN - SCOPUS:78649801132

VL - 40

SP - 102

EP - 107

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 1

ER -